Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin,
and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine
efficacy, defined as the objective response rate (ORR) of this investigational treatment. It
is hypothesized that SM-88 used with MPS will lead to significant anti-tumor responses with
acceptable toxicities in patients with metastatic HR+/HER2- breast cancer.